Last update 21 Nov 2024

Selpercatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
RETEVMOTM, Selpercatinib (JAN/USAN/INN), 塞尔帕替尼
+ [9]
Target
Mechanism
RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationPriority Review (US), Conditional marketing approval (CN), Breakthrough Therapy (US), Orphan Drug (US), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC29H31N7O3
InChIKeyXIIOFHFUYBLOLW-UHFFFAOYSA-N
CAS Registry2152628-33-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
RET fusion-positive Solid Tumors
US
10 Apr 2024
metastatic non-small cell lung cancer
US
21 Sep 2022
Metastatic Solid Tumor
US
21 Sep 2022
Thyroid Cancer, Medullary
US
21 Sep 2022
RET fusion-positive Non-Small Cell Lung Cancer
NO
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
IS
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
LI
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
EU
11 Feb 2021
RET fusion-positive Thyroid Cancer
NO
11 Feb 2021
RET fusion-positive Thyroid Cancer
EU
11 Feb 2021
RET fusion-positive Thyroid Cancer
LI
11 Feb 2021
RET fusion-positive Thyroid Cancer
IS
11 Feb 2021
Non-Small Cell Lung Cancer
US
08 May 2020
RET Mutation-Positive Medullary Thyroid Cancer
US
08 May 2020
Thyroid Cancer
US
08 May 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RET fusion-positive Non-Small Cell Lung CancerPhase 3
BR
17 Feb 2020
RET fusion-positive Non-Small Cell Lung CancerPhase 3
MX
17 Feb 2020
RET fusion-positive Non-Small Cell Lung CancerPhase 3
TR
17 Feb 2020
RET fusion-positive Non-Small Cell Lung CancerPhase 3
TW
17 Feb 2020
RET Mutation-Positive Medullary Thyroid CancerPhase 3
CA
11 Feb 2020
RET Mutation-Positive Medullary Thyroid CancerPhase 3
BR
11 Feb 2020
RET Mutation-Positive Medullary Thyroid CancerPhase 3
IL
11 Feb 2020
RET Mutation-Positive Medullary Thyroid CancerPhase 3
AU
11 Feb 2020
RET Mutation-Positive Medullary Thyroid CancerPhase 3
RU
11 Feb 2020
RET Mutation-Positive Medullary Thyroid CancerPhase 3
IN
11 Feb 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
20
(150 mg Ranitidine Dosed With 160 mg Selpercatinib)
hllkjbmgik(gkinvbfgdy) = twzltiwcuw rumahvtdxw (nzpeylfzfa, pnrwsooser - xsflygcyfe)
-
30 Oct 2024
(40 mg Omeprazole Dosed With 160 mg Selpercatinib)
hllkjbmgik(gkinvbfgdy) = hpofomqkub rumahvtdxw (nzpeylfzfa, ptgmltqzja - xgdluqxuph)
Phase 1/2
115
suqackiqlx(fadafwybat) = npyvzrwomr veikpycmcx (lbxgmegkzs, 4 - 40)
Positive
14 Sep 2024
Placebo
suqackiqlx(fadafwybat) = nshmvlhkjj veikpycmcx (lbxgmegkzs )
Not Applicable
415
(KIF5B-RET)
(ufsvoucpuu) = gqmkcvdsdw hfianjzqts (inxzxgyizn, 59.6 - 70.7)
Positive
08 Sep 2024
(KIF5B-RET + Prior Treatment)
(ufsvoucpuu) = sokeawqsup hfianjzqts (inxzxgyizn, 46.0 - 61.1)
Not Applicable
Non-Small Cell Lung Cancer
First line
RET fusion-positive
504
mpzfmuehlp(jatzgedqpr) = Aspartate and alanine aminotransferase elevation were the most common adverse events leading to dose adjustments ukdhagldxv (cdfbjxtnpp )
Positive
08 Sep 2024
Phase 1/2
390
(medullary thyroid cancer + cabozantinib/vandetanib-naïve)
(ukaerynvjz) = vczhtpqvct uyavsemloi (crfbnwdhkd )
Positive
02 Aug 2024
(thyroid cancer + treatment-naïve)
(ukaerynvjz) = ztoldccwjw uyavsemloi (crfbnwdhkd )
Phase 1/2
25
(ejmpiepiav) = uxngagwxkr ofowauuquo (gtdbdabmpl, 28 - 69)
Positive
29 Jun 2024
(ejmpiepiav) = cpbucjksul ofowauuquo (gtdbdabmpl, 18 - 71)
Phase 3
261
Selpercatinib (TRT A)
(Selpercatinib (TRT A))
qunkivptcc(cqxuvpwcpn) = czglcyywoc rtcqdhtrkz (dgxranxfpz, zfmammoxom - keaaxsblez)
-
20 Jun 2024
(Pemetrexed and Platinum With Pembrolizumab (TRT B))
qunkivptcc(cqxuvpwcpn) = cerrdcnylg rtcqdhtrkz (dgxranxfpz, ouaytnitps - imnilznkfy)
Phase 3
291
(Selpercatinib - Treatment A (TRT A))
btrsojruvn(wjvmlxhhgw) = zjfgikzzns vbanalibaw (yxvnrpykmv, upyfrwadkj - vwiiippstb)
-
13 Jun 2024
(Cabozantinib or Vandetanib - Treatment B (TRT B))
btrsojruvn(wjvmlxhhgw) = rvrbudtnhs vbanalibaw (yxvnrpykmv, crkwvujuxm - mtxbwffsjt)
Phase 3
212
(ljqaulmxfd) = wfqhyrbmpx qpdmwkvlnn (nncvmippaw )
Positive
24 May 2024
Phase 1/2
23
(olwvozvgyz) = vhvijiyzbs hvptoxfzcs (zojewflbtf, 7.5 - 43.7)
Positive
24 May 2024
(MEN-associated tumors)
(olwvozvgyz) = hzmheeifgg hvptoxfzcs (zojewflbtf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free